Erythroderma: Difference between revisions
From IDWiki
(Created page with "==Etiologies== * Inflammatory dermatoses ** Psoriasis ** Atopic dermatitis ** Other dermatitis ** Pityriasis rubra pilaris ** Lichen planus ** Chronic actinic dermatitis ** Papuloerythroderma of Ofuji ** Sarcoidosis * Drug reaction ** ACE inhibitor, particularly enalapril and lisinopril ** Allopurinol ** Bevacizumab ** Carbamazepine ** Chlorpromazine ** Dapsone ** Erythropoietin ** Gold salts ** Hydrox...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Etiologies== |
==Etiologies== |
||
* Inflammatory dermatoses |
* Inflammatory dermatoses |
||
** [[Psoriasis]] |
** '''[[Psoriasis]]''' (60%) |
||
** [[Atopic dermatitis]] |
** [[Atopic dermatitis|'''Atopic dermatitis''']] (5%) |
||
** [[Pityriasis rubra pilaris]] (<5%) |
|||
** Other dermatitis |
|||
** [[ |
** [[Polymorphic light eruption]] (<5%) |
||
** [[Dermatitis]] other than atopic |
|||
** [[Lichen planus]] |
** [[Lichen planus]] |
||
** [[Chronic actinic dermatitis]] |
** [[Chronic actinic dermatitis]] |
||
** [[Papuloerythroderma of Ofuji]] |
** [[Papuloerythroderma of Ofuji]] |
||
** [[Sarcoidosis]] |
** [[Sarcoidosis]] |
||
* |
* '''Adverse drug reaction''' (15-20%) |
||
** [[ACE inhibitor]], particularly [[enalapril]] and [[lisinopril]] |
** [[ACE inhibitor]], particularly [[enalapril]] and [[lisinopril]] |
||
** [[Allopurinol]] |
** [[Allopurinol]] |
||
| Line 35: | Line 36: | ||
* Malignancy |
* Malignancy |
||
** Hematologic |
** Hematologic |
||
*** [[Cutaneous T-cell lymphoma]], including [[ |
*** [[Cutaneous T-cell lymphoma|'''Cutaneous T-cell lymphoma''']], including [[Sézary syndrome]] and [[mycosis fungoides]] (10-15%) |
||
*** Other [[lymphoma]] |
*** Other [[lymphoma]] |
||
*** [[Leukemia]] |
*** [[Leukemia]] |
||
| Line 44: | Line 45: | ||
*** [[Colon cancer]] |
*** [[Colon cancer]] |
||
* Immunobullous disease |
* Immunobullous disease |
||
| ⚫ | |||
** [[Pemphigus foliaceus]] |
** [[Pemphigus foliaceus]] |
||
** [[Pemphigus vulgaris]] |
** [[Pemphigus vulgaris]] |
||
| ⚫ | |||
** [[Paraneoplastic pemphigus]] |
** [[Paraneoplastic pemphigus]] |
||
* Connective tissue diseases |
* Connective tissue diseases |
||
| Line 61: | Line 62: | ||
** [[Mastocytosis]] |
** [[Mastocytosis]] |
||
** [[Graft-versus-host disease]] |
** [[Graft-versus-host disease]] |
||
* Idiopathic |
|||
[[Category:Dermatology]] |
|||
Latest revision as of 16:07, 2 January 2024
Etiologies
- Inflammatory dermatoses
- Psoriasis (60%)
- Atopic dermatitis (5%)
- Pityriasis rubra pilaris (<5%)
- Polymorphic light eruption (<5%)
- Dermatitis other than atopic
- Lichen planus
- Chronic actinic dermatitis
- Papuloerythroderma of Ofuji
- Sarcoidosis
- Adverse drug reaction (15-20%)
- ACE inhibitor, particularly enalapril and lisinopril
- Allopurinol
- Bevacizumab
- Carbamazepine
- Chlorpromazine
- Dapsone
- Erythropoietin
- Gold salts
- Hydroxychloroquine
- Imatinib
- Isoniazid
- Penicillin
- Phenobarbital
- Phenytoin
- Piroxicam
- Proton pump inhibitor
- Retinoids, including acitretin and isotretinoin
- Streptomycin
- Sulfasalazine
- Terbinafine
- Thalidomide
- Co-trimoxazole
- Vancomycin
- Malignancy
- Hematologic
- Cutaneous T-cell lymphoma, including Sézary syndrome and mycosis fungoides (10-15%)
- Other lymphoma
- Leukemia
- Solid organ
- Hematologic
- Immunobullous disease
- Connective tissue diseases
- Infections
- Blood disorders
- Idiopathic
